Comparative Pharmacology
Head-to-head clinical analysis: ANECTINE versus ARDUAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANECTINE versus ARDUAN.
ANECTINE vs ARDUAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depolarizing neuromuscular blocker; mimics acetylcholine at nicotinic receptors at the neuromuscular junction, causing sustained depolarization and receptor desensitization.
Nondepolarizing neuromuscular blocking agent; competitively blocks acetylcholine at nicotinic receptors at the motor end-plate.
1-1.5 mg/kg IV bolus for intubation; maintenance infusion: 2.5-4.3 mg/min IV; alternatively, 3-4 mg/kg IM for intubation.
Initial IV bolus of 0.08 mg/kg followed by incremental doses of 0.01 mg/kg to maintain neuromuscular blockade
None Documented
None Documented
2-5 minutes (pseudocholinesterase hydrolysis); terminal half-life of succinylmonocholine ~30-60 minutes; clinical duration of apnea determined by rapid initial hydrolysis
Terminal elimination half-life approximately 2 hours (range 1.5-2.9 hours); prolonged in renal impairment
Renal: 10-15% unchanged; hepatic: rapid hydrolysis by plasma pseudocholinesterase (butyrylcholinesterase) to succinylmonocholine and succinic acid; <2% biliary; <2% fecal
Primarily renal (60-70% unchanged drug); biliary/fecal (20-30%)
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker